Vertex Pharmaceuticals (VRTX) Income towards Parent Company (2009 - 2026)

Vertex Pharmaceuticals' Income towards Parent Company history runs 18 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 59.59% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 538.7% YoY), while the FY2025 annual figure was $4.0 billion, up 838.09% from the prior year.
• Income towards Parent Company was $1.0 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.2 billion in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $1.2 billion in Q4 2025 to a low of -$3.6 billion in Q2 2024.
• Historically, Income towards Parent Company has averaged $670.0 million across 5 years, with a median of $930.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company jumped 1109.7% in 2022, then tumbled 492.44% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at $818.9 million in 2022, then increased by 18.31% to $968.8 million in 2023, then decreased by 5.76% to $913.0 million in 2024, then jumped by 30.46% to $1.2 billion in 2025, then decreased by 13.41% to $1.0 billion in 2026.
• The last three Income towards Parent Company figures came in at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.